USPTO serial 87195772
SARPODEX
Reviewed by CopyMark Law Group
Reg. 5656270Status 710
- Filing date
- Status date
- Registration date
- Jan 15, 2019
- Examiner
- JUN, WON KYUNG WENDY
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SARPODEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
VERNON HILLS, DE
EXCIVA UG (haftungsbeschränkt)
Heidelberg, DE
EXCIVA UG (haftungsbeschränkt)
Heidelberg, DE
EXCIVA UG (haftungsbeschränkt)
Heidelberg, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sreenivasarao Vepachedu
Sreenivasarao Vepachedu EXCIVA GmbH1230 GEORGETOWN WAYVERNON HILLS, IL 60061UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders | SECTION 8 - CANCELLED | Jul 2, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EXCIVA GMBH
- Other trademarks owned by EXCIVA UG (haftungsbeschränkt)
- Other trademarks owned by EXCIVA UG (haftungsbeschränkt)
- Other trademarks owned by EXCIVA UG (haftungsbeschränkt)
- Other trademarks in Class 005
- Similar marks named SARPODEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 15, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 11, 2020 | CORV | REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD | — |
| May 13, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 8, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 8, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 8, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 8, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 8, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 8, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 7, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 15, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 11, 2018 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Dec 8, 2018 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 1, 2018 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Dec 1, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 14, 2018 | IUAF | USE AMENDMENT FILED | — |
| Nov 14, 2018 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 16, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 14, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 14, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 14, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 14, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 27, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 26, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 19, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 12, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 24, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 24, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 18, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jun 11, 2017 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 1, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 1, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 27, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 27, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 27, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 16, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 16, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 16, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 13, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 17, 2016 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Oct 17, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 13, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 10, 2016 | NWAP | NEW APPLICATION ENTERED | — |